Literature DB >> 17277765

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.

Kaaren K Reichard1, Robert W McKenna, Steven H Kroft.   

Abstract

We report detailed clinical and pathologic features of four cases of anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL), a rare entity with only 29 currently reported cases. This study is the third largest of all reported series. Biopsies from four adult patients aged 41, 49, 53, and 71 years (three lymph nodes and one nasopharyngeal mass) exhibited immunoblastic/plasmablastic morphology. By immunohistochemistry and/or flow cytometry, they expressed cytoplasmic ALK-1, CD138, VS38 (3/3), monoclonal cytoplasmic light chain, CD45, EMA, CD4, and CD57 (2/3), and were negative for CD3, CD30, CD56, and TIA-1. Two showed variable CD79a expression, and one had rare CD20(+) cells. Two of three cases exhibited rare CD43(+) reactivity. One case showed scattered cytokeratin(+) cells, which could possibly lead to a misdiagnosis of carcinoma. After CHOP and radiotherapy, two stage I patients were free of disease at 58 and 36 months, whereas a stage IV patient was dead of disease at 22 months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277765     DOI: 10.1038/modpathol.3800742

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Yasunori Ota; Yasunobu Sekiguchi; Satoko Hatano; Reimi Asaka; Masaaki Noguchi; Hiroyuki Mano
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

Review 2.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

Review 3.  Nodal aggressive B-cell lymphomas: a diagnostic approach.

Authors:  Sonam Prakash; Steven H Swerdlow
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

4.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 5.  Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting in nasal cavity: a case report and review of literature.

Authors:  Ji Chen; Xiaoli Feng; Mei Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 6.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

7.  CD4-positive diffuse large B cell lymphoma identified by flow cytometry: two case reports.

Authors:  Marisa Arrondini; Antonella Barreca; Sabrina Aliberti; Anna Demurtas; Fabrizio Tondat; Domenico Novero; Alessandra Stacchini
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

Review 8.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

9.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.